Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
12/2010
12/01/2010CN101899108A Novel polypeptide based on human TLR9 receptor functional domain segment LRR11 and applications thereof
12/01/2010CN101899106A Trimeric binding proteins for trimeric cytokines
12/01/2010CN101899105A Recombinant erythropoietin and preparation method thereof
12/01/2010CN101899104A Low molecular weight peptide of shark cartilage angiogenesis inhibiting factor, production purifying method and application thereof
12/01/2010CN101899100A Anti-HIV-I (Human Immunodeficiency Virus-I) polypeptides as well as coding sequences and applications thereof
12/01/2010CN101899099A X4 peptide synthetic product and application thereof
12/01/2010CN101899095A Centipede toxin anti-tumour active polypeptide
12/01/2010CN101899093A X2 polypeptide synthesis product and application thereof.
12/01/2010CN101899091A Fatty alkyl pentapeptide conjugate, preparation method thereof and application thereof in medical science
12/01/2010CN101899090A Saturated fatty chain alcohol His-Gly-AA tripeptide ester, synthetic method and application thereof
12/01/2010CN101899089A Saturated fatty chain amine His-Gly-AA tripeptide amide, synthetic method and application thereof
12/01/2010CN101899088A Saturated fat chain acid His-Gly-AA tripeptide amide, and synthesis method and use thereof
12/01/2010CN101899087A Saturated fatty chain amine Glu-Asp-Gly tripeptide amides as well as synthesis method and application thereof
12/01/2010CN101899086A Saturated fatty chain acid Glu-Asp-Gly tripeptide amide, synthetic method and application thereof
12/01/2010CN101899085A Saturated fatty chain alcohol Glu-Asp-Gly tripeptide ester, synthetic method and application thereof
12/01/2010CN101899084A (3S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid kyrine conjugate, preparation method and application thereof
12/01/2010CN101897974A Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins
12/01/2010CN101897970A Compositions and methods for treating diabetes
12/01/2010CN101897969A Use of complement inhibitors in preparing medicines for preventing or treating tissure damage
12/01/2010CN101897959A Recombinant human pancreatic kininogenase-containing medicine for treating and/or preventing cerebral infarction
12/01/2010CN101897958A Superoxide dismutase eye drops and preparation method thereof
12/01/2010CN101897957A New application of orexin
12/01/2010CN101897956A External use recombinant human neuropeptide Y nanoemulsion and preparation method thereof
12/01/2010CN101897955A Cell factor composition for immune regulation
12/01/2010CN101897954A Composition, preparation method thereof and use thereof
12/01/2010CN101897953A Non-invasive high-penetrability epidermal growth factor and application thereof
12/01/2010CN101897952A Application of trefoil factor 3 to preparing medicament for preventing and/or treating depressive disorder
12/01/2010CN101897951A Anti-inflammatory effect of novel anti-inflammatory molecular DRP, implementation method and application
12/01/2010CN101897950A Antiviral actions, implementation method and use of novel antiviral molecule DRP
12/01/2010CN101897949A Ophthalmic medicament composition for forming low-irritation transparent emulsion formulation for surface immune adjustment and inflammation reduction of relevant tissue of eyes or eye periphery
12/01/2010CN101897948A Application of S-nitroso glutathione
12/01/2010CN101897947A Nutritional compositions for controlling blood glucose level
12/01/2010CN101897731A External spraying agent based on complex biological acid
12/01/2010CN101897724A Method for producing a soft tissue filler and method for producing an adipose tissue transplant
12/01/2010CN101560478B Bacillus subtilis subso natto for producing natto kinase and application thereof
12/01/2010CN101323643B Optimized TACI-Fc fuse protein
12/01/2010CN101229185B Medicine compounds for treating seriously disease
12/01/2010CN101190941B Polypeptide with thrombus dissolving activity and its preparation method and application
12/01/2010CN101058808B Breast cancer relevant p60 gene, coding protein and application thereof
12/01/2010CN101016332B Short peptide for inhibiting Shiga toxin and application thereof
11/2010
11/30/2010US7842790 Immunoglobulin fusion for use in treating eating disorders associated with tumor growth and therapeutics
11/30/2010US7842788 Metalloproteinase specific immunoglobulin for use in treatment and prevention of degradative diseases of connective tissue
11/30/2010US7842784 Antagonizing bone morphogenetic protein activity; utilizing polypeptide comprising amino acids 22-452 of sequence 8; bone diseases, tissue regeneration, wound healing
11/30/2010US7842780 Silk fibroin materials and use thereof
11/30/2010US7842719 Use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis C, bovine viral diarrhea and classical swine fever virus
11/30/2010US7842699 administering 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile or salts, for the treatment of dermatitis, Crohn's disease, inflammatory bowel disease, transplant rejection, lupus, multiple sclerosis, arthritis, psoriasis, diabetes and autoimmune diseases
11/30/2010US7842683 Beta-lactam antibiotics and beta-lactamase inhibitors provide significant neurotropic effects in warm-blooded vertebrates evidenced inter alia by anxiolytic and antiaggressive behavior modification and enhanced cognition
11/30/2010US7842671 Blocking cancer cells; antiproliferative agents; inducting apoptosis; anticancer, antitumor agents; peptidomimetics
11/30/2010US7842670 administering to the skin an effective amount of a peptide of a amino acid sequence ( (AA)n-Gly-Leu-Tyr-Asp-Asn-Leu-Glu-(AA)n ;(AA) is any particular amino acid, n= 0 to 3) able to activate endogenous synthesis of sirtuin (SIRT1) protein; cosmetic dermo-pharmaceutical, or dermatological formulation
11/30/2010US7842669 administering to the site of the full thickness defect of articular cartilage, an osteochondral graft , an active growth factor e.g. purified bone morphogenetic protein (BMP) and a suitable carrier for the regeneration of the cartilage
11/30/2010US7842668 providing 1 mg/ml to 20 mg/ml Apo-2 ligand, 0.2 M to 0.5M arginine salt (arginine succinate, phosphate, citrate etc.) a buffer, polysorbate surfactant, mixing the ingredients to make a formulation, adjusting the pH of the formulation to 6 to 9; therapeutical and diagnostic use
11/30/2010US7842667 Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same
11/30/2010US7842666 Inhibitors of myelin-associated glycoprotein (MAG) activity for regulating neural growth and regeneration
11/30/2010US7842665 pro-inflammatory cytokines, interleukins (IL-17A, IL-17F)
11/30/2010US7842664 Synthetic lipid mixtures for the preparation of a reconstituted surfactant
11/30/2010US7842663 activins (ActRIIB), for modulating (promoting or inhibiting) growth of tissue such as bone, cartilage, muscle, fat, and/or neuronal tissue; fusion proteins which inhibit signaling by myostatin and/or growth differentiation factor 11 in cell-based assay; drug screening; pharmacokinetics
11/30/2010US7842662 of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma
11/30/2010US7842661 Glycopegylated erythropoietin formulations
11/30/2010US7842503 Hybrid recombinases for genome manipulation
11/30/2010US7842502 in vitro use of granulocyte chemotactic protein-2 (CXCL6) to promote cartilage (and underlying bone) formation e.g. in the repair of cartilage or osteochondral defects; osteoarthritis
11/30/2010US7842489 Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof
11/30/2010US7842480 Protein fusion comprising transport domain for use in treatment and prevention of viral inection and cell proliferative disorders
11/30/2010US7842477 Methods for producing gamma-carboxylated proteins
11/30/2010US7842470 Method for pharmacoperones correction of GnRHR mutant protein misfolding
11/30/2010US7842458 Amino acid sequences for use in diagnosis, prevention and detection of cancer
11/30/2010US7842453 Methods of identifying modulators of ChemerinR polypeptides
11/30/2010US7842314 periodically administering neuraminidase to a lukemia patient
11/30/2010US7842311 for oral dosage; for treatment of pain; sustained release
11/30/2010US7842310 Pharmaceutical compositions in particulate form
11/30/2010US7842309 Tamper-resistant oral opioid agonist formulations
11/30/2010US7842297 raising an antibody specific for Chlamydia trachomatis elementary bodies (EB) in which a protein of the present invention is administered to a patient
11/30/2010US7842296 Sequences from Piscirickettsia salmonis
11/30/2010US7842295 Canine influenza virus and related compositions and methods of use
11/30/2010US7842294 useful in vaccine compositions for treatment of cancer; human major histocompatibility complex (MHC) Class I restricted peptides; kits
11/30/2010US7842290 involved in the adaptation of microorganisms to its environment, particularly the identification of genes responsible for the virulence of a pathogenic microorganisms
11/30/2010US7842280 solid phase peptide synthesis for a peptidyl contrast agent; synthesizing an amino-chelator loaded resin coupling the loaded resin to C-terminus and/or backbone of a peptide, cleaving the amino-chelator-peptide from a resin, and chelating a lanthanide metal; DOTA or DTPA chelate coupled to peptide
11/30/2010CA2430772C Humanized antibodies that recognize beta amyloid peptide
11/30/2010CA2383324C Solution for the preservation of hearts
11/30/2010CA2295876C Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
11/30/2010CA2259595C Dna immunization against chlamydia infection
11/30/2010CA2193969C Peptide, a method of obtaining it and a pharmaceutical compound based on it
11/30/2010CA2189740C Transgenic arthritic mice
11/25/2010WO2010135736A2 Application and uses of prg4 and therapeutic modulation thereof
11/25/2010WO2010135684A2 Bone morphogenetic proteins for the treatment of insulin resistance
11/25/2010WO2010135662A2 Marker differentially expressed in cancer stem cells and methods of using same
11/25/2010WO2010135655A2 Human skin substitutes expressing il-12
11/25/2010WO2010135541A2 Variants of c-type natriuretic peptide
11/25/2010WO2010135527A2 Elastin for soft tissue augmentation
11/25/2010WO2010135491A2 Fibroblast growth factor mutants having improved functional half-life and methods of their use
11/25/2010WO2010135459A2 Brain delivery of insulin to treat systemic inflammation
11/25/2010WO2010135277A2 Cyclic-glur6 analogs, methods of treatment and use
11/25/2010WO2010135242A1 Combinations of immunostimulatory agents, oncolytic virus, and additional anticancer therapy
11/25/2010WO2010134970A1 Inhibition of prion protein propagation by receptor associated protein (rap). its derivatives, mimetics and syntentic peptides
11/25/2010WO2010134939A2 Mammalian genes involved in infection
11/25/2010WO2010134851A1 Agent for the prophylaxis and treatment of highly pathogenic infectious diseases
11/25/2010WO2010134827A1 Extended acting oxygen generating composition for treating microbial infections
11/25/2010WO2010134814A2 Means and methods for counteracting polyq expansion disorders
11/25/2010WO2010134806A1 Use of lipoprotein lipase (lpl) in therapy
11/25/2010WO2010134686A2 Soluble myostatin pro-domain recombinant protein having myostatin inhibitory activity and use thereof
11/25/2010WO2010134537A1 Cell membrane-permeable peptides
1 ... 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 ... 3163